There are 2867 resources available
1743P - ALTN-AK105-II-02 cohort 4: A phase II study of penpulimab plus anlotinib in patients (pts) with previously treated locally advanced or metastatic urothelial carcinoma (UC)
Presenter: Yongkun Sun
Session: Poster session 17
1744P - Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study
Presenter: Haifeng Li
Session: Poster session 17
1746P - Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)
Presenter: Cora Sternberg
Session: Poster session 17
1747P - Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study
Presenter: Ronald De Wit
Session: Poster session 17
1748P - 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)
Presenter: Guru Sonpavde
Session: Poster session 17
1749P - Association between immune-mediated adverse events (imAEs) and outcomes in metastatic urothelial cancer (mUC) treated with durvalumab (D) alone or in combination with tremelimumab (T) in the DANUBE study
Presenter: Osama Abdeljalil
Session: Poster session 17
1750P - Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England
Presenter: Craig Knott
Session: Poster session 17
1751P - Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies
Presenter: Prianka Deshmukh
Session: Poster session 18
1752P - Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011
Presenter: Yohann Loriot
Session: Poster session 18